Arix Bioscience PLC has released its unaudited estimated Net Asset Value (NAV) for December 2023. The total NAV for the company as of 31 December 2023 is £59.2 million, with a breakdown showing £66.2 million in listed portfolio, £106.2 million in unlisted portfolio, £2.6 million in cash, and £234.2 million in other interests. The NAV per share is £1.81. Arix Bioscience PLC is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. They collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients.
As a listed company, Arix Bioscience PLC aims to bring this exciting growth phase of the industry to a broader range of investors. For more information, interested parties can contact Arix Bioscience PLC directly or visit their website.